Navigation Links
NCC and Wyeth Donation to Assist Cancer Patients in Latin America
Date:1/14/2009

LIMA, Peru, Jan. 14 /PRNewswire/ -- The National Cancer Coalition (NCC) and Wyeth Pharmaceuticals (Wyeth) are pleased to announce a pilot program to assist cancer patients in Latin America with donations of Wyeth's cancer-related medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) (oprelvekin).

United States Ambassador Michael McKinley and the Peruvian Health Ministry participated in a hand-over event held at the Instituto Nacional de Enfermadades Neoplacias (INEN) in Lima, along with representatives from National Cancer Coalition, Wyeth Pharmaceuticals, INEN, and the Peruvian media. This donation to INEN, which is the largest public cancer hospital in Peru, consists of life-saving medicines valued at over $500,000.

Ambassador McKinley stated, "The event we are celebrating today is very important for several reasons. First, because this donation is the light of hope for many cancer patients in Peru who, due to the large quantity of medicines being donated today, will have access to life-saving treatment. In addition, this event is very special because it underscores the importance of public-private partnerships and the concrete gains that can be achieved with these partnerships to meet the critical health care needs of our citizens."

Eduardo Nieto, President, Wyeth Pharmaceuticals, Latin America, commented, "Wyeth is dedicated to aiding patients in need, and we are honored to be partnering with NCC in this initiative to provide oncology medicines to underserved patients in Peru."

"National Cancer Coalition is pleased that this new program with Wyeth Pharmaceuticals will lead to greater oncology resources for patients in the developing world. Through this donation, it is anticipated that over 100 Peruvian leukemia patients will be helped at INEN this year. NCC looks forward to expanding our medicine donation initiatives with Wyeth, as we jointly seek to help patients who would otherwise lack access to their required specialty medicines," stated Robert B. Landry, President of NCC. In the last five years, NCC has provided over $9 million worth of donated cancer medicines to INEN hospitals.

National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports cancer relief, research and educational programs throughout the world. The Coalition's international medical assistance program, termed NCC Cares, provides requested pharmaceuticals, medical equipment, and hospital supplies to public hospitals and local humanitarian organizations that help needy patients in over 40 developing countries around the world.

For additional information, please contact National Cancer Coalition at: 919-821-2182 or visit our website at http://www.nationalcancercoalition.org.


'/>"/>
SOURCE National Cancer Coalition
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
2. Wyeth to Present at the JP Morgan Healthcare Conference
3. SmartOps Enterprise Inventory Optimization Software Licensed by Wyeth Pharmaceuticals
4. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
5. Wyeth Sets Webcast and Conference Call for 2008 Fourth Quarter and Full Year Earnings
6. Wyeth to Present at the Credit Suisse Healthcare Conference
7. The Senior Citizens Leagues Comments on U.S. Supreme Court Case Wyeth v. Levine
8. Wyeth v. Levine: Preemption and The Facts
9. Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
10. Wyeth Selected for 11th Consecutive Year as One of Working Mother Magazines 100 Best Companies for Working Mothers
11. Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... TX (PRWEB) , ... February 27, 2017 , ... ... 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential Customer ... Energy LLC in March 2014. The company had 800 customers and 2,250 RCEs ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/27/2017)... ... ... New Jersey ranks among the top five states in the entire nation ... advanced services is growing. , Project WE vs C is a focused two-year ... non-profit partners in their fight against cancer and in support of their shared mission ...
(Date:2/26/2017)... Como, Italy (PRWEB) , ... February 26, 2017 ... ... its last call for entries to the 7th Edition of International Social Design ... by Social Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: